Quick Answer
Vir Biotechnology, Inc. reported Stockholders Equity of $2.08 billion for the year ending 2022.
- Vir Biotechnology, Inc. showed an increase of +45.1% in Stockholders Equity from 2021 to 2022.
- This data is from Vir Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 28, 2023.
- XBRL data for this metric is available from 2016 to 2022 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$122.30 million | Q3 2018: -$154.02 million | Q1 2019: -$205.22 million | Q2 2019: -$236.97 million | Q3 2019: -$280.80 million | Q1 2020: $380.33 million | Q2 2020: $563.78 million | Q3 2020: $812.36 million | Q1 2021: $650.95 million | Q2 2021: $737.33 million | Q3 2021: $876.27 million | Q1 2022: $2.00 billion | Q2 2022: $1.95 billion | Q3 2022: $2.15 billion | Q4 2022: $2.08 billion | Q1 2023: $1.97 billion | Q4 2023: $1.59 billion | Q1 2024: $1.55 billion | Q2 2024: $1.43 billion | Q3 2024: $1.24 billion | Q4 2024: $1.15 billion | Q1 2025: $1.04 billion | Q2 2025: $947.47 million | Q3 2025: $796.10 million.
- Over the full 7 years of available data (2016 to 2022), Vir Biotechnology, Inc.'s Stockholders Equity has grown by 26,165.8%.
- Historical annual values: Fiscal year 2022: $2.08 billion | Fiscal year 2021: $1.43 billion | Fiscal year 2020: $716.85 million | Fiscal year 2019: $423.94 million | Fiscal year 2018: -$179.18 million | Fiscal year 2017: -$68.92 million | Fiscal year 2016: -$7.97 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: